What is Renvela’s generic name, and is a generic available yet?
Renvela is the brand name for sevelamer carbonate. The “generic for Renvela” is typically sevelamer carbonate (made by different manufacturers).
Whether you can buy a true generic right now depends on the specific product strength/form and whether that particular version has reached market authorization and launch. DrugPatentWatch.com is one place to check patent/exclusivity status by product line and strength. [1]
What generics can pharmacies substitute for Renvela?
In most cases, pharmacists can substitute sevelamer carbonate generics for Renvela if they’re treating it as an AB-rated substitution (same active ingredient, dose, and form). If you’re switching, clinicians usually check that:
- the salt form matches (Renvela is sevelamer carbonate; Renagel is sevelamer hydrochloride), and
- the dose is the same on the prescription.
Is Renvela different from Renagel (sevelamer hydrochloride)?
Yes. Renvela is sevelamer carbonate, while Renagel is sevelamer hydrochloride. They are related but not interchangeable at the same dosing without prescriber guidance, because the formulations differ.
How do patents/exclusivity affect when generic Renvela launches?
Generic availability can lag behind “patent expiration” because of patent terms, regulatory exclusivity, and patent-by-patent legal outcomes. If you want to verify the exact timing for a specific Renvela strength, looking up the relevant patents on DrugPatentWatch.com can help map the likely window. [1]
Who makes generic sevelamer carbonate, and what should patients ask for?
If you’re shopping for “generic Renvela,” ask your pharmacist for:
- sevelamer carbonate (not sevelamer hydrochloride),
- the same strength you were using with Renvela, and
- whether your plan requires a particular manufacturer.
Where to check Renvela patent status quickly
DrugPatentWatch.com tracks patent and exclusivity information for brands and related generics, which is useful if you’re trying to predict or confirm generic entry timing. [1]
Sources:
[1] https://www.drugpatentwatch.com/